Core Viewpoint - The acceptance of the clinical trial application for the "recombinant trivalent rotavirus subunit vaccine (E. coli)" marks a significant milestone in the company's innovative vaccine development process, indicating progress in its recombinant protein vaccine strategy based on its E. coli technology platform [1] Group 1 - The clinical trial application for the vaccine has been accepted by the National Medical Products Administration [1] - The vaccine is intended for the prevention of rotavirus gastroenteritis [1] - Successful development and future market launch of this product could enhance the company's product portfolio and increase its market competitiveness [1]

Core Viewpoint - Wante Bio (603392.SH) has received approval from the National Medical Products Administration for its self-developed HIV1+2 antibody oral mucosal exudate test kit, marking a significant advancement in self-testing for HIV in China [1] Group 1 - The product is the first of its kind in China approved for self-testing of HIV1+2 antibodies in oral mucosal exudate [1] - This approval follows the company's previous successful launches of HIV1 urine antibody test kits and HIV1+2 antibody test kits, showcasing its continuous innovation in the field [1] - The approval reinforces the company's leading technological position and innovative capabilities in the area of self-testing for HIV [1]

证券代码：603392 证券简称：万泰生物 公告编号：2025-069 北京万泰生物药业股份有限公司 关于重组三价轮状病毒亚单位疫苗（大肠埃希菌） 临床试验申请获得受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京万泰生物药业股份有限公司（以下简称"公司"）全资子公司厦门 万泰沧海生物技术有限公司收到国家药品监督管理局（以下简称"国家药监局"） 行政许可文书《受理通知书》，公司申报的"重组三价轮状病毒亚单位疫苗（大肠 埃希菌）"临床试验申请已获得受理。现将相关情况公告如下： 一、药品基本信息 产品名称：重组三价轮状病毒亚单位疫苗（大肠埃希菌） 申请事项：境内生产药品注册临床试验 受理号：CXSL2501136 适应症：适用于预防轮状病毒胃肠炎 此次重组三价轮状病毒亚单位疫苗（大肠埃希菌）临床试验申请的受理，是 公司创新疫苗研发过程中的重要一步，标志着公司基于大肠埃希菌自主技术平台 的重组蛋白疫苗研发战略又取得关键进展，若该产品研发未来成功上市，将有利 于丰富公司产品布局，进一步提高公司市场竞争力。 截至 2 ...

证券代码：603392 证券简称：万泰生物 公告编号：2025-068 北京万泰生物药业股份有限公司 关于 HIV 抗体口腔黏膜渗出液自我检测试剂 取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京万泰生物药业股份有限公司（以下简称"公司"）自主研发的人 类免疫缺陷病毒（HIV1+2 型）抗体口腔黏膜渗出液检测试剂盒（胶体金法）取 得国家药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试 剂）》。现将相关信息公告如下： 一、注册证主要信息 注册人住所：北京市昌平区科学园路 31 号 产品名称：人类免疫缺陷病毒（HIV1+2 型）抗体口腔黏膜渗出液检测试剂 盒（胶体金法） 包装规格：1 人份/盒，10 人份/盒，50 人份/盒。 预期用途：用于体外定性检测人口腔黏膜渗出液中的人类免疫缺陷病毒 （HIV1+2 型）抗体，可用于消费者自测。 二、产品其他信息 该产品是国内首个获批的用于自测口腔黏膜渗出液中的人类免疫缺陷病毒 （HIV1+2 型）抗体的试剂盒，这是公司继人类免疫缺陷病毒 1 ...

Core Viewpoint - Wantai Biological Pharmacy (603392.SH) has received acceptance for its clinical trial application for the "Recombinant Trivalent Rotavirus Subunit Vaccine (E. coli)" from the National Medical Products Administration, marking a significant step in the company's innovative vaccine development process [1] Group 1 - The acceptance of the clinical trial application is a crucial advancement in the company's recombinant protein vaccine development strategy based on its proprietary E. coli technology platform [1] - Successful future commercialization of this product could enhance the company's product portfolio and further improve its market competitiveness [1]

Core Viewpoint - Wante Bio (603392.SH) has received approval from the National Medical Products Administration for its self-developed HIV1+2 antibody oral mucosal exudate test kit, marking a significant advancement in self-testing for HIV in China [1] Group 1: Product Approval - The product is the first of its kind in China approved for self-testing of HIV1+2 antibodies in oral mucosal exudate [1] - This approval follows the company's previous successful launches of HIV1 urine antibody test kits and HIV1+2 antibody test kits, showcasing its continuous innovation in the field [1] Group 2: Market Position - The approval reinforces the company's leading technological position and innovative capabilities in the self-testing domain for HIV [1]

Core Viewpoint - Wanta Biotechnology (603392.SH) has received acceptance for its clinical trial application for the "Recombinant Trivalent Rotavirus Subunit Vaccine (E. coli)" from the National Medical Products Administration, marking a significant step in the company's vaccine development process [1] Group 1 - The acceptance of the clinical trial application is a crucial advancement in the company's innovative vaccine research and development [1] - This development signifies a key progress in the company's recombinant protein vaccine research strategy based on its proprietary E. coli technology platform [1] - Successful future commercialization of this product could enhance the company's product portfolio and further improve its market competitiveness [1]

北京万泰生物药业股份有限公司（以下简称"公司"）于2025年10月15日召开第六届董事会第十次会议、 第六届监事会第十次会议，并于2025年10月31日召开2025年第一次临时股东会，审议并通过了《关于变 更部分回购股份用途并注销的议案》。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 统一社会信用代码：91110114600067778R 类型：其他股份有限公司（上市） 登录新浪财经APP 搜索【信披】查看更多考评等级 公司因回购专用证券账户中已回购但尚未使用的729,970股股份用途由"用于员工持股计划或股权激 励"变更为"用于注销并减少注册资本"。本次变更部分回购股份用途后，公司回购专用证券账户中的 729,970股已于2025年12月17日在中国证券登记结算有限责任公司完成注销。注销完成后公司总股本由 1,265,122,774股减少至1,264,392,804股，注册资本由1,265,122,774元减少至1,264,392,804元。具体内容详 见公司于2025年12月17日在指定信息披露媒体披露的《北京万泰生物 ...

Group 1: Hydrogen Energy Development - Fujian has prioritized the hydrogen energy industry as a key strategic direction for green energy development, establishing innovation laboratories and conducting forward-looking research since 2019 [2][3] - The hydrogen storage and transportation technology is a critical challenge for the hydrogen industry, with Fuzhou University leading efforts to develop ammonia as an efficient hydrogen storage carrier [2] - A hydrogen industry working group has been established in Fujian to address urgent technical issues and promote collaborative breakthroughs across the entire hydrogen value chain [3] Group 2: Technological Innovation Platforms - Fujian supports the establishment of high-level scientific innovation platforms led by private enterprises to enhance the integration of technology and industry [4] - The Ningde Times Innovation Laboratory, co-built with the Ningde municipal government, has accelerated the development of new battery technologies, enabling rapid product launches [4][5] - Ningde Times has invested over 80 billion yuan in R&D, employing over 20,000 personnel and holding more than 43,000 patents, positioning itself as a leader in the global new energy sector [5] Group 3: Biopharmaceutical Industry Focus - Fujian has made significant strides in the biopharmaceutical sector, exemplified by the launch of the domestically developed nine-valent HPV vaccine, which enhances accessibility for women [6][7] - The establishment of the Xiang'an Innovation Laboratory aims to facilitate the transformation of biopharmaceutical innovations into practical applications, improving the success rate of technology transfer [7] - Fujian's government has implemented targeted policies to strengthen the biopharmaceutical innovation ecosystem, focusing on health needs and enhancing the overall industry chain [6][7]

证券日报网讯 12月23日晚间，万泰生物发布公告称，公司回购专用证券账户中的729，970股已于2025 年12月17日在中国证券登记结算有限责任公司完成注销。注销完成后公司总股本由1，265，122，774股 减少至1，264，392，804股，注册资本由1，265，122，774元减少至1，264，392，804元。近日，公司 完成了工商变更登记手续，并取得了北京市昌平区市场监督管理局换发的《营业执照》。 （编辑 袁冠琳） ...